MolecuLight enters distribution agreement with Smith & Nephew
Medical imaging company MolecuLight (Toronto, ON, Canada) has entered into an exclusive global distribution agreement with medical technology investor Smith & Nephew (Kingston upon Hull, England) to distribute its MolecuLight i:X imaging device. The device offers real-time fluorescence image-guidance solutions that provide new information about wound bacterial burden and wound size, with the goal of assisting clinicians in making improved diagnostic and treatment decisions.
Related: Fluorescence microscopy method sheds light on poor wound healing in diabetics
The MolecuLight i:X device enables healthcare professionals to see the actual accumulation of fluorescent bacteria in a wound, even when not visible to the naked eye, explains Andy Weymann, MD, chief medical officer at Smith & Nephew. It also offers guiding debridement, wound cleansing, and wound measurement, he says.
The device is currently CE-Marked and approved by Health Canada, and is available in the European Union and Canada. It is pending De Novo approval in the U.S.
For more information, please visit www.moleculight.com.
BioOptics World Editors
We edited the content of this article, which was contributed by outside sources, to fit our style and substance requirements. (Editor’s Note: BioOptics World has folded as a brand and is now part of Laser Focus World, effective in 2022.)